M. Gaudinski

发表

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

J. Mascola, T. Pierson, C. Andrews, 2017, The Lancet.

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults

J. Mascola, A. Namboodiri, R. Koup, 2018, PLoS medicine.

Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial

J. Mascola, D. Baltimore, E. Boritz, 2022, Nature Medicine.

Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial.

J. Mascola, A. Namboodiri, R. Koup, 2019, The lancet. HIV.

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial.

J. Mascola, R. Bailer, B. Graham, 2021, The Lancet. Respiratory medicine.

A proof of concept for structure-based vaccine design targeting RSV in humans

J. Mascola, P. Kwong, B. Graham, 2019, Science.

Clonal hematopoiesis is not significantly associated with COVID-19 disease severity

F. Rieux-Laucat, L. Notarangelo, K. Dobbs, 2022, Blood.

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of mAb114: A Phase 1 Trial of a Therapeutic Monoclonal Antibody Targeting Ebola Virus Glycoprotein

J. Mascola, R. Koup, N. Sullivan, 2019 .

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial

J. Mascola, R. Koup, T. Zhou, 2022, EClinicalMedicine.

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization

J. Mascola, D. Montefiori, P. Roberts, 2021, medRxiv.

Atopic Dermatitis and Allergic Urticaria: Cutaneous Manifestations of Immunodeficiency.

J. Milner, M. Gaudinski, 2017, Immunology and allergy clinics of North America.

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.

J. Mascola, Zonghui Hu, A. McDermott, 2022, The New England journal of medicine.

A Monoclonal Antibody for Malaria Prevention.

J. Mascola, Zonghui Hu, A. McDermott, 2021, The New England journal of medicine.

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization

J. Mascola, D. Montefiori, P. Roberts, 2021, medRxiv.

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

J. Mascola, D. Montefiori, N. Sullivan, 2022, The New England journal of medicine.

Clinical outcomes and immune responses to SARS‐CoV‐2 vaccination in severe aplastic anaemia

R. Koup, A. McDermott, Madhu S. Prabhakaran, 2022, British journal of haematology.

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones

Chaim A. Schramm, Alexander M Schrager, J. Mascola, 2022, bioRxiv.

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

J. Mascola, R. Baric, N. Sullivan, 2020, The New England journal of medicine.

Safety and Efficacy of a Monoclonal Antibody against Malaria in Mali.

Peter D. Crompton, Zonghui Hu, A. McDermott, 2022, The New England journal of medicine.

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

Chaim A. Schramm, J. Mascola, R. Baric, 2021, bioRxiv.

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

J. Mascola, R. Baric, E. Boritz, 2021, Science.

Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants.

Chaim A. Schramm, Alexander M Schrager, J. Mascola, 2022, bioRxiv : the preprint server for biology.

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

J. Mascola, R. Koup, C. Andrews, 2023, The Lancet.

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study

J. Mascola, R. Koup, C. Andrews, 2019, The Lancet.

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants

Chaim A. Schramm, J. Mascola, R. Baric, 2021, Science.

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

J. Mascola, R. Koup, J. Casazza, 2022, Nature Medicine.

Establishing Final Infarct Volume: Stroke Lesion Evolution Past 30 Days Is Insignificant

M. Luby, S. Warach, L. Latour, 2008, Stroke.

Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality

J. Mascola, A. Barrett, T. Pierson, 2020, Science Translational Medicine.

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses.

Chaim A. Schramm, J. Mascola, D. Douek, 2021, Immunity.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults

Carmen M. Graves, J. Mascola, R. Koup, 2023, Science Translational Medicine.

Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials

J. Mascola, J. Ledgerwood, L. Corey, 2021, Journal of acquired immune deficiency syndromes.

Feridex Preloading Permits Tracking of CNS-Resident Macrophages after Transient Middle Cerebral Artery Occlusion

S. Warach, L. Latour, J. Hallenbeck, 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.

Zonghui Hu, A. McDermott, J. Gall, 2023, The Lancet. Infectious diseases.